ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial

Friday, September 4, 2015

Submitted by

Mark Ferguson

Source

Source Name: Annals of Thoracic Surgery

Source URL: http://www.annalsthoracicsurgery.org/article/S0003-4975%2815%2900846-2/abstract

Author(s)

Vinod H. Thourani, Hanna A. Jensen, Vasilis Babaliaros, Susheel K. Kodali, Jeevanantham Rajeswaran, John Ehrlinger, Eugene H. Blackstone, Rakesh M. Suri, Creighton W. Don, Gabriel Aldea, Mathew R. Williams, Raj Makkar, Lars G. Svensson, James M. McCabe, Larry S. Dean, Samir Kapadia, David J. Cohen, Augusto D. Pichard, Wilson Y. Szeto, Howard C. Herrmann, Chandan Devireddy, Bradley G. Leshnower, Gorav Ailawadi, Hersh S. Maniar, Rebecca T. Hahn, Martin B. Leon, Michael Mack.

Short- and mid-term outcomes of TAVR for nonagenarian (>90 years) patients in the PARTNER-1 trial were assessed for 531 pts. MACE occurred in 35% including stroke in 3.6%. Important paravalvular leak occurred in 1.4%. 30-day mortality was 4% and 3-year mortality was 48%, which compared to 44% in a matched population. QOL stabilized at 6 months and was better than preop. A trans-apical approach had a higher risk of 30-day and 3-year mortality.